CHDR Annual Report 2025
Contents 2025
  • Homepage
  • 2025 in perspective
  • Developing drugs
  • Developing methods
  • Developing people
  • 2025 stories
Other years

Developing drugs

CHDR’s research groups made vital contributions to the development of new drugs in 2025. In this we are proud to collaborate with a range of valued clients and partners, some of whom also share their stories below.

NeuroKit® test used in the United Kingdom

‘Reproducible results thanks to objective measurements’ – Dr Gerard Marek, Gilgamesh Pharma

Complex study provided insight into immunological pathways

'The next step in an immunological journey of discovery' – Professor Frédéric Triebel, Immutep

Favourable results for AMPA-PAM osavampator

Novel treatments for patients with atopic dermatitis

Promising results from a novel psychedelic compound

New CO2 challenge setup ready for proof-of-mechanism studies with anxiolytic drugs

Novel therapy for rheumatoid arthritis studied in healthy participants and in patients

Successful next step for potential treatment of frontotemporal dementia

Genotyped cohort facilitates recruitment for studies in Parkinson's Disease

Back to homepage
  • © CHDR 2026
  • +31 (0)71 5246400
  • info@chdr.nl
  • www.chdr.nl